EcoR1 Capital’s C4 Therapeutics CCCC Stock Holding History

EcoR1 Capital’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-200,000	Closed	-$4.85M	–	83
2022 Q1	$4.85M	Hold	200,000	–	–	0.15%	54
2021 Q4	$6.44M	Hold	200,000	–	–	0.21%	44
2021 Q3	$8.94M	Hold	200,000	–	–	0.31%	36
2021 Q2	$7.57M	Hold	200,000	–	–	0.28%	38
2021 Q1	$7.4M	Hold	200,000	–	–	0.33%	37
2020 Q4	$6.63M	Buy	+200,000	New	+$5.8M	0.36%	35

Other funds holding CCCC

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

EcoR1 Capital's CCCC Position: Q2 2022 in Review

EcoR1 Capital sold out of C4 Therapeutics (CCCC) in Q2 2022, closing a stake of 200,000 shares — an estimated $4.85M sold.

EcoR1 Capital first reported a position in CCCC in Q4 2020 and held it in 6 quarters. The position peaked at $8.94M in Q3 2021. 113 funds tracked by Wall St. Rank hold CCCC as of Q2 2022.

EcoR1 Capital reported no remaining C4 Therapeutics position as of Q2 2022 after selling out during the quarter.
EcoR1 Capital sold 200,000 C4 Therapeutics shares in Q2 2022, an estimated $4.85M.
EcoR1 Capital first reported a position in C4 Therapeutics in Q4 2020 and held it in 6 quarters.
EcoR1 Capital's C4 Therapeutics position peaked at $8.94M in Q3 2021.
113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2022.

Based on EcoR1 Capital's 13F filing for Q2 2022, filed 15 Aug 2022.